BlackRock, Inc. 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | BlackRock, Inc. BLK | 6,689,435 7.500% | -1,328,857 (-16.57%) | Filing |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | BlackRock, Inc. BLK | 8,018,292 9.400% | 28,272 (+0.35%) | Filing |
| 2024-01-24 09:46 am Purchase | 2023-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | BlackRock, Inc. BLK | 7,990,020 10.600% | 287,792 (+3.74%) | Filing |
| 2023-10-06 2:34 pm Purchase | 2023-09-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | BlackRock, Inc. BLK | 7,702,228 10.300% | 2,507,443 (+48.27%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | BlackRock, Inc. BLK | 5,194,785 8.100% | 679,640 (+15.05%) | Filing |
| 2022-02-02 7:18 pm Sale | 2021-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | BlackRock, Inc. BLK | 4,515,145 7.400% | -310,029 (-6.43%) | Filing |